Study design
tumor
TUMOR
The DONIMI trial is an investigator-initiated phase 1b trial that tested the feasibility and safety of neoadjuvant combinations of nivolumab ± ipilimumab with domatinostat according to the IFN-γ score in the tumor. Patients with a high IFN-γ score in their baseline tumor biopsy (